FDA InspectionAurobindo Pharma USA Inc
Aurobindo Pharma USA Inc – FDA Inspection, May 15, 2024
Record Details
This FDA Inspection record concerns Aurobindo Pharma USA Inc, with an inspection on May 15, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
ID · 653906f9-7952-4bff-9baa-c6b093dcc401
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1238442
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- FDCA 582(b)(4)Systems in place to comply with verification requirements
- FDCA 582(b)(4)(B)(ii)(I)Notify FDA and immediate trading partners of illegitimate product
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Aurobindo Pharma USA Inc
4| Date | Classification | Office | Project area |
|---|---|---|---|
| June 4, 2026 | Not classified | New Jersey District Office | |
| December 12, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 30, 2012 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| July 29, 2011 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Or discuss it with
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every Aurobindo Pharma USA Inc document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA